Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Torudokimab in Moderate-to-Severe Atopic Dermatitis
NCT03831191Phase 2Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2019
- Primary completion
- Feb 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of torudokimab in atopic dermatitis (AD), sponsored by Eli Lilly and Company. Started Feb 2019; status: terminated.
02
Drugs
torudokimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03831191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03831191.